BGM Group Business Summary

BGM Group Ltd. (BGM), formerly Qilian International Holding Group Limited, is a diversified holding company that has rapidly pivoted from traditional pharmaceutical manufacturing to an AI-driven technology model. The company generates revenue through two primary business segments: Biopharmaceuticals, which produces oxytetracycline APIs, licorice-based medicines (Gan Di Xin), and heparin sodium; and its high-growth AI & Technology division, which commercializes the DuXiaoBao and Bao Wang platforms. These platforms provide AI-as-a-Service (AIaaS) and intelligent robotics solutions tailored for the insurance and healthcare sectors, utilizing big data and AI agents to automate underwriting, claims processing, and customer marketing. BGM competes directly with specialty pharmaceutical and biotech firms such as Kodiak Sciences (KOD), Biohaven (BHVN), and Relay Therapeutics (RLAY), positioning itself as a tech-enabled disruptor that integrates legacy chemical production with advanced AI PaaS capabilities. The leadership team is currently spearheaded by Co-CEOs Chen Xin and Li Yuqing, following a significant strategic reshuffle in early 2026. Chen Xin, who also serves as Chairman, brings a deep technical pedigree as a former algorithm engineer at DJI and Geely and holds a Ph.D. in Physics from the National University of Singapore. Co-CEO Li Yuqing, appointed in January 2026, is a former senior executive at Didi Chuxing and a specialist in AI PaaS architecture. The board was further strengthened in 2026 with the appointments of finance veteran Lou Zefei and marketing expert Yuehua Ren, alongside AI architecture specialist Lin Zhang. Notable institutional backing includes a significant stake from AIFU Inc. (formerly AIX Inc.), which became a major shareholder following the strategic acquisition of its insurance technology assets.